Advances in Inhaled Formulations for Pulmonary Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 50
Special Issue Editor
Interests: drug delivery to the lung; formulations for dry powder inhalers; formulations for nebulisers; nanosuspension for inhaled
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Developing a safe and effective form of inhalable therapy requires a pharmacologically active molecule/drug that has been combined with a well-designed delivery system and formulation. Inhaled formulations are used to treat a range of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, lung cancer, cystic fibrosis, and pulmonary infections, as well as to deliver systemic medications via the lungs.
In recent years, significant progress has been made in inhaled formulations due to the pressing need to improve inhalable drug therapeutic efficacy, enhance the treatment of respiratory diseases, minimise side effects, improve drug delivery efficiency, and increase patient compliance. For example, inhaled nanoparticle-based formulations have been utilised to enhance drug solubility, stability, and targeted delivery within the lungs. Moreover, drugs have been encapsulated in liposomal inhalation therapies to improve their stability and bioavailability. Additionally, inhaled formulations are being explored for biologics, macromolecules, and gene therapies, opening new avenues for treating conditions like cystic fibrosis, asthma, and lung cancer. Furthermore, inhaled formulations for combination therapy are another recent advancement in the field of inhalable formulation research.
This Special Issue seeks to compile the cutting-edge research and innovative developments that are transforming the landscape of inhalable formulations, including novel inhalable nano-formulations, novel inhalable gene therapies and biologics formulations, extended-release inhaled formulations, targeted pulmonary delivery strategies, 3D printing in inhalation formulations, smart inhalers, and any other advanced inhaler technologies. In addition, personalised medicine in inhalation and the latest regulatory and safety consideration studies are welcome.
Dr. Khaled Assi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inhaled biologic
- inhaled combination therapy
- inhaled gene therapy
- inhaled nanoparticles
- novel inhalable nano-formulation
- stability
- solubility
- smart inhalers
- three-dimensional printing
